February 2025- TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced the expansion of its executive leadership team with the appointment of three seasoned industry leaders:

• Chris Crisman as Chief Commercial Officer ;
• Lynne Kelley, M.D. as Chief Medical Officer ;
• Thomas Chabanis as General Counsel.

Christophe Bancel, CEO of TISSIUM, commented: ‘‘We are thrilled to welcome Chris, Lynne, and Thomas to TISSIUM at this pivotal time. Each brings invaluable expertise and leadership that will help propel our mission to revolutionize tissue reconstruction. Chris’ extensive experience in commercial strategy will be critical as we initiate commercialization and scale our market presence. Lynne’s deep medical and clinical knowledge will strengthen our innovation, evidence generation, and market adoption strategy, ensuring we bring high-impact solutions to patients. And Thomas’ legal expertise will be instrumental as we navigate the complexities of our growing business. Together, they will play a key role in shaping the future of TISSIUM.’’

Also Read : Cincinnati Children’s appoints Dr. Eric Williams as chief quality officer